- Home
- SAN vs ZTS Comparison
SAN vs ZTS Comparison
Compare SAN & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAN
- ZTS
- Stock Information
- Founded
- SAN 1857
- ZTS 1952
- Country
- SAN Spain
- ZTS United States
- Employees
- SAN 208080
- ZTS N/A
- Industry
- SAN Commercial Banks
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- SAN Finance
- ZTS Health Care
- Exchange
- SAN Nasdaq
- ZTS Nasdaq
- Market Cap
- SAN 68.3B
- ZTS 80.4B
- IPO Year
- SAN 1987
- ZTS 2013
- Fundamental
- Price
- SAN $4.51
- ZTS $163.87
- Analyst Decision
- SAN Buy
- ZTS Strong Buy
- Analyst Count
- SAN 1
- ZTS 9
- Target Price
- SAN N/A
- ZTS $220.33
- AVG Volume (30 Days)
- SAN 3.2M
- ZTS 2.6M
- Earning Date
- SAN 01-29-2025
- ZTS 02-11-2025
- Dividend Yield
- SAN 4.77%
- ZTS 1.05%
- EPS Growth
- SAN 21.62
- ZTS 8.38
- EPS
- SAN 0.83
- ZTS 5.32
- Revenue
- SAN $53,301,360,675.00
- ZTS $9,152,000,000.00
- Revenue This Year
- SAN N/A
- ZTS $9.48
- Revenue Next Year
- SAN $1.03
- ZTS $4.92
- P/E Ratio
- SAN $5.25
- ZTS $31.00
- Revenue Growth
- SAN 8.26
- ZTS 9.33
- 52 Week Low
- SAN $3.83
- ZTS $144.80
- 52 Week High
- SAN $5.27
- ZTS $200.53
- Technical
- Relative Strength Index (RSI)
- SAN 34.88
- ZTS 29.38
- Support Level
- SAN $4.83
- ZTS $163.37
- Resistance Level
- SAN $4.76
- ZTS $181.85
- Average True Range (ATR)
- SAN 0.07
- ZTS 3.88
- MACD
- SAN -0.03
- ZTS -1.22
- Stochastic Oscillator
- SAN 6.52
- ZTS 5.06
About SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.